Drug evaluation: ProCord - a potential cell-based therapy for spinal cord injury.
Proneuron Biotechnologies Inc is developing ProCord, an activated macrophage cell therapy, for the potential treatment of neurological conditions. In September 2004, ProCord was granted Orphan Drug status by the US Food and Drug Administration for the treatment of acute spinal cord injury.
Kigerl
Kristina
K
Department of Molecular Virology, Immunology & Medical Genetics, Department of Neuroscience, Ohio State University College of Medicine, 2078 Graves Hall, 333 West 10th Avenue, Columbus, OH 43210, USA.
Popovich
Phillip
P